Glenmark Generics Inc, the US arm of Glenmark Generics has received final abbreviated new drug approval from the US Food and Drugs Administration for its Mupirocin ointment, which is an antibacterial used to treat skin infection called impetigo.
Mupirocin ointment had annual sales of USD 55 million in the year ended March 2011, and grew 9% from a year ago, the company said citing IMS sales data.
Glenmark Generics, which is a subsidiary of India’s Glenmark Pharmaceuticals, has 68 products authorized for distribution in the US and 39 others are pending abbreviated new drug approval from the US FDA, the company said.
"In addition to these internal filings, Glenmark Generics Inc continues to identify and explore external development partnership to supplement and accelerate the growth of the existing pipeline and portfolio," it said in a notice to stock exchanges.
Glenmark Pharma shares were traded up 1.8% at Rs 314.70 on NSE in morning trade.
source-moneycontrol
stevenson
management trainee-fundamental analyst
DENIP Consultants Pvt Ltd.
No comments:
Post a Comment